Furafylline is a methylxanthine derivative that was introduced in hope of being a long-acting replacement for theophylline in the treatment of asthma.[1] It is an inhibitor of CYP1A2.[1]

Furafylline
Clinical data
ATC code
  • None
Identifiers
  • 3-(Furan-2-ylmethyl)-1,8-dimethyl-7H-purine-2,6-dione
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC12H12N4O3
Molar mass260.253 g·mol−1
3D model (JSmol)
  • Cc1[nH]c2c(n1)n(c(=O)n(c2=O)C)Cc3ccco3
  • InChI=1S/C12H12N4O3/c1-7-13-9-10(14-7)16(6-8-4-3-5-19-8)12(18)15(2)11(9)17/h3-5H,6H2,1-2H3,(H,13,14) ☒N
  • Key:KGQZGCIVHYLPBH-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

References

edit
  1. ^ a b Sesardic D, Boobis AR, Murray BP, Murray S, Segura J, de la Torre R, Davies DS (June 1990). "Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man". British Journal of Clinical Pharmacology. 29 (6): 651–63. doi:10.1111/j.1365-2125.1990.tb03686.x. PMC 1380167. PMID 2378786.